Emergent BioSolutions Inc said the U.S. Food and Drug Administration approved its treatment for inhaled anthrax, triggering a $7 million milestone payment from the Department of Health and Human Services (HHS).
The company developed the treatment, Anthrasil, as part of a $160 million contract it signed in 2005 with the Biomedical Advanced Research and Development Authority (BARDA), a part of the HHS.
Health for America is pleased to announce that Medstar will host the 2015-16 Health for America Fellowship in Washington D.C., in partnership with the global startup incubator, 1776.
The Fellowship will give a small group of exceptional young healthcare leaders the opportunity to put aside their day-to-day work and focus instead on finding high-impact, low-cost solutions for patients suffering from chronic diseases. Led by the MedStar Institute for Innovation (MI2), the 2015 Fellowship will give fellows broad access to providers, entrepreneurs, and other experts throughout MedStar, a regional not-for-profit health system advancing the practice of medicine through education, innovation and research.
BHI President and CEO Rich Bendis to Present
With 800+ life sciences companies, Over 70 federal labs and world class academic and research institutions, the biotechnology cluster in Maryland, Virginia, and Washington, DC sets the bar for biotechnology innovation. Join us for an event that will spotlight a world class technology community that has accounted for 1/3 of all job growth in Maryland and has been a significant economic driver for the region over the past decade.
World renowned speakers, industry luminaries and commercial giants will convene for this unique Maryland Regional Biotech Forum to highlight the accomplishments of today and chart our successes of tomorrow.
Frederick City and the County have agreed to partner with the state to help Medimmune expand.
Last week, the County Council agreed to participate with the Maryland Department of Business and Economic Development’s Maryland Economic Development Assistance and Authority Fund (MEDAAF) to provide a $1.5-million loan to Medimmune.
New Enterprise Associates expects to hold a final close next month.
Venture capital firm New Enterprise Associates has secured approximately $2.57 billion in capital commitments for its fifteenth fund, Fortune has learned.
Johns Hopkins brings to mind the renowned research university and hospital in Baltimore.
The latter has been the working home to such medical lights as neurosurgeon Ben Carson, who led a pioneering separation of twins born fused together at the cranium.
That these institutions are known primarily for the work they do, not for the person whose money gave them life, would sit just fine with their founding donor.
If you listen to large tech companies, they will tell you they are in dire need of another bailout from scary “patent trolls” who burden them with frivolous lawsuits. This tech bailout will come in the form of a bill that would weaken 225 years of U.S. patent law to help big companies always win, and guarantee that small innovators and inventors will always lose.
The United States’ patent law system is at the foundation of American global success, found in breakthrough discoveries from Edison to the computer chip to recombinant DNA. Do we really need to “fix” the legal system that has enabled America to become number one in the global biotech, software, hardware, medical devices, energy, genomics, and nanotechnology industries? Patent filings are down an astonishing 40% in 2014 as a result of the first patent troll “fix” a few years ago and recent court decisions that have given away our nation’s competitive edge.
The National Institutes of Health has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices, and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded at $9 million over three years.
Gaithersburg-based Emergent BioSolutions Inc. is adding a $31 million contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to its ongoing work developing a next-generation anthrax vaccine.
The BARDA contract is for NuThrax, a vaccine that requires fewer doses, has a higher immune response and has no need for refrigeration.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
Requests for Applications:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
